Trial Profile

A Phase-3b, Partially Double-blind, Randomized, Multi-country Clinical Study to Evaluate the Immunogenicity,Safety, and Reactogenicity of SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant quadrivalent Serum Institute of India (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
Indications Human papillomavirus infections
Focus Pharmacodynamics
Sponsors Serum Institute of India

29 Jun 2026 Planned End Date changed from 1 Dec 2026 to 31 Dec 2027.
29 Jun 2026 Planned primary completion date changed from 1 Jun 2026 to 31 Dec 2026.
29 Jun 2026 Status changed from not yet recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com